U.S. Psychedelic Drugs Market is Expected to Grow at 16.3% in the Forecast Period of 2020 to 2027

U.S. Psychedelic Drugs Market is forecasted to grow at 16.3% with factors such as increasing prevalence of depression and mental disorders driving the growth of the U.S. psychedelic drugs market

U.S. psychedelic drugs market has shown an increasing prevalence of depression and mental disorders which are increasing demand of psychedelic drugs. Although, regulations imposed on psychedelic drugs restricts the growth of the market.

U.S. Psychedelic Drugs Market Scenario

According to Data Bridge Market Research Jazz Pharmaceuticals, Inc. is the leader for U.S. psychedelic drugs market and this company holds estimated market share of approximately 70% to 80% of the market. The market leader Jazz Pharmaceuticals, Inc. accounts an estimated market share of approximately 75.00% in the U.S. Jazz Pharmaceuticals, Inc. is a leader in psychedelic drugs in the U.S. and additionally, the company is continuously involved in the development of new products to increase its portfolio of psychedelic drugs. The psychedelic drugs sales revenue of Jazz Pharmaceuticals, Inc. has increased drastically by 16% to generate sales revenue of USD 1,525.18 million 2019 as compared to 2018.

• In October 2018, Jazz Pharmaceuticals plc has received FDA Authorization for Xyrem (sodium oxybate) for the excessive daytime sleepiness or cataplexy treatment in pediatric narcolepsy patients.  The authorization will help company to dominate the market as Xyrem is one and only FDA approved treatment available for cataplexy and excessive daytime sleepiness in narcolepsy for adult patients.

Trends impacting the market

The U.S. psychedelic drugs market is becoming more competitive every year with companies such as Johnson & Johnson Services, Inc. and Jazz Pharmaceuticals, Inc., the market leaders for U.S. psychedelic drugs Market. The data bridge market research new reports highlight the major growth factors and opportunities in the U.S. psychedelic drugs market.

For more analysis on the U.S. psychedelic drugs market request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=us-psychedelic-drugs-market

Scope of the U.S. Psychedelic Drugs Market

All country based analysis of the U.S. psychedelic drugs market is further analyzed based on maximum granularity into further segmentation. On the basis of source, the market is segmented into synthetic and natural. On the basis of type, the market is segmented into dissociatives, empathogens and serotonergic (classical psychedelic drugs). On the basis of application, the market is segmented into narcolepsy, treatment-resistant depression, posttraumatic stress disorder, major depressive disorder and others. On the basis of route of administration, the market is segmented into oral, intranasal, parenteral and others. On the basis of drugs, the market is segmented into Gamma Hydroxybutyric Acid (GHB), Ketamine, 3, 4- Methylenedioxymethamphetamine (Ecstasy) and Psilocybin. On the basis of end user, the market is segmented into hospitals, speciality clinic, research organization and others. On the basis of distribution channel, the market is segmented into hospital pharmacy, compounding pharmacy and others.

To know more about the study https://www.databridgemarketresearch.com/reports/us-psychedelic-drugs-market

Key Pointers Covered in the U.S. Psychedelic Drugs Market Industry Trends and Forecast to 2027

• U.S. psychedelic drugs market Size
• Psychedelic drugs Regulatory Framework and Changes
• Psychedelic Drugs Pipeline
• Mental Disorders Epidemiology
• Practicing Psychiatrists Data
• Psychedelic drugs Recent Developments for Market Competitors
• Psychedelic drugs Recent market value for different regions
• Psychedelic drugs sales data for Market Competitors
• Psychedelic drugs key vendors and disruptors study

Key Market Competitors Covered in the report

• Johnson & Johnson Services, Inc.
• Jazz Pharmaceuticals, Inc.
• Celon Pharma SA
• COMPASS
• usonainstitute.org
• Develco pharma schweiz ag
• Doughlas pharmaceuticals limited
• NeuroRX, Inc.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals, LLC.
• AVADEL PHARMACEUTICALS, PLC

Above are the key players covered in the report, to know about more and exhaustive list of psychedelic drugs companies contact us https://www.databridgemarketresearch.com/toc/?dbmr=us-psychedelic-drugs-market

Research Methodology: U.S. Psychedelic Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

• Demand Side: Dermatologists, Psychiatrists, Researchers, Practitioners, and activists, Academician, Distributors, Hospitals, Nurses, and Industrial Professionals.
• Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Report

• Global Psychedelic Drugs Market - Industry Trends and Forecast to 2026

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/